- ￥5000
- EK-Bioscience
- CCC-Y1788
- 2025年07月10日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 规格：
T25
DMS 153、DMS 153、DMS 153细胞、DMS 153细胞、DMS 153人小细胞肺癌细胞
Cell line name DMS 153
Synonyms DMS-153; DMS153; Darmouth Medical School 153
Accession CVCL_1175
Resource Identification Initiative To cite this cell line use: DMS 153 (RRID:CVCL_1175)
Comments Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
Population: Caucasian.
Doubling time: 28 days (PubMed=6266631); 5.8 days (PubMed=2986244).
Omics: Deep exome analysis.
Omics: Deep proteome analysis.
Omics: Protein expression by reverse-phase protein arrays.
Omics: SNP array analysis.
Omics: Transcriptome analysis by microarray.
Omics: Transcriptome analysis by RNAseq.
Derived from site: Metastatic; Liver; UBERON=UBERON_0002107.
Sequence variations
Mutation; HGNC; 11998; TP53; Simple; p.Thr155Pro (c.463A>C); Zygosity=Homozygous (PubMed=14660794; DepMap=ACH-000594).
Genome ancestry Source: PubMed=30894373
Origin % genome
African 0.64
Native American 0.56
East Asian, North 3.7
East Asian, South 0
South Asian 0
European, North 51.44
European, South 43.66
Disease Lung small cell carcinoma (NCIt: C4917)
Small cell lung cancer (ORDO: Orphanet_70573)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Originate from same individual CVCL_Z033 ! DMS 154
Sex of cell Male
Age at sampling 44Y
Category Cancer cell line
STR profile Source(s): ATCC=CRL-2064; CCRID; ECACC=95062827; PubMed=25877200
Markers:
Amelogenin X (ATCC=CRL-2064; CCRID)
X,Y (ECACC=95062827; PubMed=25877200)
CSF1PO 10
D2S1338 17,20
D3S1358 14,17 (PubMed=25877200)
17 (ATCC=CRL-2064; CCRID)
D5S818 12
D6S1043 11,18
D7S820 8,10
D8S1179 12,14
D13S317 12,13 (PubMed=25877200)
13 (ATCC=CRL-2064; CCRID; ECACC=95062827)
D16S539 12,13
D18S51 16,17
D19S433 12.1,15
D21S11 26.2,30
FGA 21
Penta D 9,12
Penta E 12 (ATCC=CRL-2064; CCRID)
12,13 (PubMed=25877200)
TH01 7,9.3
TPOX 11
vWA 14,15
Run an STR similarity search on this cell line
Publications
PubMed=6266631; DOI=10.1002/1097-0142(19800301)45:5<906::AID-CNCR2820450513>3.0.CO;2-H
Pettengill O.S., Sorenson G.D., Wurster-Hill D.H., Curphey T.J., Noll W.W., Cate C.C., Maurer L.H.
Isolation and growth characteristics of continuous cell lines from small-cell carcinoma of the lung.
Cancer 45:906-918(1980)
PubMed=2986244; DOI=10.1007/978-3-642-82372-5_5
Vindelov L.L., Hansen H.H., Spang-Thomsen M.
Growth characteristics and heterogeneity of small cell carcinoma of the lung.
Recent Results Cancer Res. 97:47-54(1985)
PubMed=9744504; DOI=10.1038/bjc.1998.553; PMCID=PMC2063065
Damstrup L., Voldborg B.G.R., Spang-Thomsen M., Brunner N., Poulsen H.S.
In vitro invasion of small-cell lung cancer cell lines correlates with expression of epidermal growth factor receptor.
Br. J. Cancer 78:631-640(1998)
PubMed=12712436; DOI=10.1002/ijc.11106
Hansen L.T., Lundin C., Spang-Thomsen M., Petersen L.N., Helleday T.
The role of RAD51 in etoposide (VP16) resistance in small cell lung cancer.
Int. J. Cancer 105:472-479(2003)
PubMed=14660794; DOI=10.1073/pnas.2536558100; PMCID=PMC307654
Kanashiro C.A., Schally A.V., Groot K., Armatis P., Bernardino A.L.F., Varga J.L.
Inhibition of mutant p53 expression and growth of DMS-153 small cell lung carcinoma by antagonists of growth hormone-releasing hormone and bombesin.
Proc. Natl. Acad. Sci. U.S.A. 100:15836-15841(2003)
PubMed=20164919; DOI=10.1038/nature08768; PMCID=PMC3145113
Bignell G.R., Greenman C.D., Davies H.R., Butler A.P., Edkins S., Andrews J.M., Buck G., Chen L., Beare D., Latimer C., Widaa S., Hinton J., Fahey C., Fu B.-Y., Swamy S., Dalgliesh G.L., Teh B.T., Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Signatures of mutation and selection in the cancer genome.
Nature 463:893-898(2010)
PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458; PMCID=PMC2881662
Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P., Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J., Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C., Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J., Haber D.A.
A genome-wide screen for microdeletions reveals disruption of polarity complex genes in diverse human cancers.
Cancer Res. 70:2158-2164(2010)
PubMed=22460905; DOI=10.1038/nature11003; PMCID=PMC3320027
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.-Y.K., Yu J.-J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L.E., Winckler W., Reich M., Li N.-X., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M.L., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)
PubMed=22961666; DOI=10.1158/2159-8290.CD-12-0112; PMCID=PMC3567922
Byers L.A., Wang J., Nilsson M.B., Fujimoto J., Saintigny P., Yordy J., Giri U., Peyton M., Fan Y.-H., Diao L.-X., Masrorpour F., Shen L., Liu W.-B., Duchemann B., Tumula P., Bhardwaj V., Welsh J., Weber S., Glisson B.S., Kalhor N., Wistuba I.I., Girard L., Lippman S.M., Mills G.B., Coombes K.R., Weinstein J.N., Minna J.D., Heymach J.V.
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
Cancer Discov. 2:798-811(2012)
PubMed=25877200; DOI=10.1038/nature14397
Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M., Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S., Neve R.M.
A resource for cell line authentication, annotation and quality control.
Nature 520:307-311(2015)
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验*发表【中文论文】请标注：由上海酶研生物科技有限公司提供；
*发表【英文论文】请标注：From Shanghai EK-Bioscience Biotechnology Co., Ltd.
方法。 应用这种技术可以检测靶 DNA 中 G 残基的优先甲基化，对尔后的蛋白质结合作用究竟会有什么效应，从而更加详细的揭示出 DNA 与蛋白质相互作用的模式。 2. 实验步骤： 用 DMS 处理靶 DNA 使之局部甲基化（平均每条 DNA 只发生一个 G 碱基甲基化作用）同细胞蛋白质提取物一起进行温育，促进使 DNA 与蛋白质的结合 进行凝胶电泳形成两种靶 DNA 条带： （1）其一没有同蛋白质结合的 DNA 正常电泳条带 （2）其二同特异蛋白质结合而呈现滞后的 DNA 电泳条带 将这两种 DNA 电泳
说来，不论稀释与否，将细胞从一个培养瓶转移或移植到另一个培养瓶即称为传代或传代培养。可以理解，在任何时候，细胞从一个瓶子接种到另一个瓶子时总会丢失一部分，因此，在客观上细胞必定有所稀释。传代代数这一概念常常容易同「增殖代数」相混淆。细胞「一代」一词仅指从细胞接种到分离再培养时的一段时间。如某一细胞系为第 153 代，即指该细胞系已传代 153 次。它与细胞「增殖代数」（细胞世代或倍增）不同，在细胞一代中，细胞约能倍增 3～6 次。由此可见，细胞代数与增殖代数相关，确切的代数则依赖于细胞株和培养条件的不同而异
对甲基化的G残基作特异性的化学切割这一原理设计的另一种研究蛋白质同DNA相互作用的实验方法。 应用这种技术可以检测靶DNA中G残基的优先甲基化，对尔后的蛋白质结合作用究竟会有什么效应，从而更加详细的揭示出DNA与蛋白质相互作用的模式。 2. 实验步骤： 用DMS处理靶DNA使之局部甲基化（平均每条DNA只发生一个G碱基甲基化作用）同细胞蛋白质提取物一起进行温育，促进使DNA与蛋白质的结合 进行凝胶电泳形成两种靶DNA条带： （1）其一没有同蛋白质结合的DNA正常电泳条带
技术资料